Navigation Links
New discovery is a significant boost to cancer research
Date:4/4/2010

A team of scientists led by the University of East Anglia (UEA) has discovered a brand new group of molecules which could help fight the spread of cancer and other diseases.

The new molecules are synthetic derivatives of a natural product known as UDP-Galactose, and block the activity of a group of enzymes called glycosyltransferases. Glycosyltransferases are used by biological cells to turn simple sugars into elongated sugar chains and branched structures.

Published online today by the journal Nature Chemical Biology, the findings could lead to a significant therapeutic advance in the treatment of cancer, inflammation and infection.

Many biological cells - including cancer cells and bacterial cells - are literally covered by a coating of sugar. This sugar coating influences the way cells communicate with their environment and with each other.

For example, when a cancer spreads through the body or a bacterium infiltrates its human host many of the contacts the rogue cells make with other cells are through these sugars on their cell surface.

To form the complex sugar structures that decorate their surface, cells rely on gylcosyltransferases to join individual sugar building blocks together. The UEA researchers have found that synthetic UDP-Galactose derivatives block these enzymes effectively. These molecules can therefore potentially be used to interfere with harmful biological processes such as cancer metastasis and bacterial infection.

The work was carried out by researchers at UEA's School of Pharmacy, working alongside colleagues at the Carlsberg Research Centre in Denmark.

"This exciting discovery of a potent enzyme inhibitor with a completely new mechanism of action has considerable therapeutic potential in cancer, inflammation and infection," said lead author Dr Gerd Wagner of UEA.

"Our results also provide a general strategy for how to design and improve such inhibitors in the future. The 'snapshots' we have taken of one of these enzymes, together with the new inhibitor itself, can provide very valuable guidance for the development of new anti-cancer and anti-infective drug candidates."


'/>"/>

Contact: Press office
press@uea.ac.uk
44-016-035-93496
University of East Anglia
Source:Eurekalert

Related biology news :

1. Queens University professors chemistry discovery may revolutionize cooking oil production
2. Discovery that PARP protein exists in all breast tumors will help target chemo and predict response
3. Chance discovery leads to plant breeding breakthrough
4. A-maize-ing discovery could lead to higher corn yields for food, feed and fuel
5. African bird discovery proves there is something new under the sun
6. Discovery in legumes could reduce fertilizer use, aid environment: Stanford researchers
7. Startup joins UCLA tech incubator to develop technologies for drug discovery, screening
8. An electrifying discovery: New material to harvest electricity from body movements
9. New gene discovery could help to prevent blindness
10. First discovery of the female sex hormone progesterone in a plant
11. Enlisting a drug discovery technique in the battle against global warming
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/28/2017)... 2017   Acuant , a leading provider of ... enhancements to new and core technologies building upon the ... mobile and desktop Acuant FRM TM facial recognition ... real time manual review of identity documents by accredited ... fastest and most accurate capture software to streamline workflows ...
(Date:2/27/2017)... , Feb. 27, 2017   Strategic Cyber ... announced it has led a $3.5 million investment in  ... platform. Strategic Cyber Ventures is DC based and is ... Hank Thomas . Ron Gula , also ... Ventures, also participated in this series A round of ...
(Date:2/22/2017)... Feb. 22, 2017 With the biometrics ... Research identifies four technologies that innovative and agile ... significant share in the changing competitive landscape: multifactor ... authentication.   "Companies can no longer ... security," says Dimitrios Pavlakis , Industry Analyst ...
Breaking Biology News(10 mins):
(Date:3/22/2017)... ... March 21, 2017 , ... Proper glycosylation ... on the desired increase and/or decrease in antibody-dependent cellular cytotoxicity or complement-dependent cytotoxicity, ... of therapeutic antibodies. , To meet this demand, the team at SCIEX ...
(Date:3/22/2017)... , ... March 21, 2017 , ... The Conference Forum ... (CMO Summit) to be held on May 10-11, 2017, at the Colonnade Hotel in ... specifically for Chief Medical Officer peer-to-peer learning, benchmarking and support. , “The Chief Medical ...
(Date:3/22/2017)... ... 2017 , ... The Society for Immunotherapy of Cancer (SITC) strongly opposes the ... published fiscal year 2018 budget request. , This proposal calls for ... or roughly 20% of its total budget. If applied proportionally across NIH, funding for ...
(Date:3/22/2017)... , March 22, 2017  Personal Genome ... its cancer testing contract with the U.S. Department ... tumor profiling assay with the company,s new CancerSELECT ... comprehensive, clinically actionable pan-cancer profiling test that includes ... assess potential patient response to checkpoint inhibitor immunotherapies. ...
Breaking Biology Technology: